We have included important factors in the cautionary statements included in this Annual Report, particularly in “Item 3. No forward-looking statement is a guarantee of future performance. You should read this Annual Report completely and with the understanding that our actual future results may be materially different from what we expect.
Partnerships Cumberland Pharmaceuticals: Exclusive Joint Commercialization Agreement — U.S. commercialization via jointly controlled Talicia Holdings (RedHill 70% equity interest; profits shared equally). Gaelan Medical: UAE and Middle East commercialization
Indications
H. pylori infection in adults(Approved)
Status note First and only internally developed FDA-approved product. RedHill no longer directly commercializes Talicia; rights sold to Movantik sold separately.
RHB-102
Stage not disclosed · Active
Target 5-HT3
Partnerships Hyloris Pharmaceuticals (Feb 2025 exclusive license): responsible for development, manufacture, registration and commercialization in granted territories
Status note Out-licensed to Hyloris; this filing's extraction did not state indication or stage.
RHB-104
Stage not disclosed · Active
Indications
Crohn's disease(Stage not disclosed)
Status note Filing flags development/approval risk absent a validated MAP lab test; stage not stated in this excerpt.
RHB-204
Stage not disclosed · Active
Indications
Crohn's disease(Stage not disclosed)
Status note Stage not stated in this excerpt.
Per-asset detail extracted from the 20-F filed 2026-04-27. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.